Enhancing sleep, wakefulness, and cognition with transcranial photobiomodulation: a systematic review
- PMID: 40822571
- PMCID: PMC12350269
- DOI: 10.3389/fnbeh.2025.1542462
Enhancing sleep, wakefulness, and cognition with transcranial photobiomodulation: a systematic review
Abstract
Disruptions in sleep are common across clinical populations, particularly those with neurological and psychiatric disorders, making restorative sleep and sustained wakefulness a public health priority. Sleep is essential for brain function, impacting cognition in addition to serving as a critical factor in memory consolidation and healthy aging. Neuromodulation via transcranial photobiomodulation (t-PBM) increases cerebral mitochondrial activity and blood flow. These effects may underlie improvements in sleep quality and wakefulness observed after t-PBM. In this systematic review, we summarize the current literature across clinical and healthy populations, which describes t-PBM's potential to improve sleep, wakefulness, and cognition. The scope of this review also includes t-PBM's effect on the brain's glymphatic system and blood flow, the potential of this strategy to augment alertness, wakefulness, and associated cognitive processes, and the suggestion for targeted t-PBM application for future research based on the underlying neurobiological mechanisms of t-PBM and wakefulness across diverse clinical populations.
Keywords: cognition; sleep; sleep disorders; transcranial photobiomodulation; wakefulness.
Copyright © 2025 Gaggi, Parincu, Peterson, O’Brien, Kam, Tural, Ayappa, Varga, Iosifescu and Osorio.
Conflict of interest statement
DI has served as a consultant for Alkermes, Allergan, Angelini, Autobahn, Axsome, Biogen, Boehringer Ingelheim, the Centers for Psychiatric Excellence, Clexio, Delix, Jazz, Lundbeck, Neumora, Otsuka, Precision Neuroscience, Relmada, Sage Therapeutics, and Sunovion. He has received grant support (paid to his institutions) from Alkermes, AstraZeneca, BrainsWay, LiteCure, NeoSync, Otsuka, Roche, and Shire. RO has served as a consultant for Idorsia. AV has served as a consultant for Jazz, Eisai, and Merck pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.Cochrane Database Syst Rev. 2014 Apr 29;2014(4):CD007768. doi: 10.1002/14651858.CD007768.pub3. Cochrane Database Syst Rev. 2014. PMID: 24777444 Free PMC article.
-
Wakefulness can be distinguished from general anesthesia and sleep in flies using a massive library of univariate time series analyses.PLoS Biol. 2025 Jul 10;23(7):e3003217. doi: 10.1371/journal.pbio.3003217. eCollection 2025 Jul. PLoS Biol. 2025. PMID: 40638578 Free PMC article.
-
Short-Term Memory Impairment.2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31424720 Free Books & Documents.
-
Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults.Cochrane Database Syst Rev. 2023 Aug 18;8(8):CD013244. doi: 10.1002/14651858.CD013244.pub2. Cochrane Database Syst Rev. 2023. PMID: 37593770 Free PMC article.
References
-
- Bogdanova Y., Ho V., Martin P., Ho M., Yee M., Hamblin M., et al. (2017). Transcranial LED treatment for cognitive dysfunction and sleep in chronic TBI: Randomized controlled pilot trial. Arch. Phys. Med. Rehabil. Database 98 E122–E123. 10.1016/j.apmr.2017.08.398 - DOI
Publication types
LinkOut - more resources
Full Text Sources